Trends in the incidence of Rifampicin resistant Mycobacterium tuberculosis infection in northeastern Nigeria

Ibrahim, Muhammad Bello; Isyaka, Tom M.; Askira, Umoru M.; Umar, Jidda B.; Isa, Mustafa Alhaji; Mustapha, Adam; Salihu, Akbar

doi:10.1016/j.sciaf.2022.e01341

Cited by 4 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence rate of M. tuberculosis (18.33%) in this study was higher than the previous study reported 6.5% [14] and 7.9% [15] in Ethiopia, 13.8% [16] in Nepal, and 12% [17] in India. The incidence rate of M. tuberculosis infection among total suspects (n=39107) tested for Xpert MTB/RIF was 18.33% (7156/39107), which is lower than the previous study reported 38.77% [18] in China, 22.65 % [19], 22.9% [20] in Nigeria and 23.82% [21] in India. The 3.26% positivity among the 8581 Extrapulmonary samples tested for tuberculosis using Xpert MTB/RIF assay in this study is lower than the previous study (13%) conducted by Anwar et.al.…”

Section: Discussioncontrasting

confidence: 59%

“…In a previous study, Ibrahim et al [19] reported the incidence of M.tuberculosis and rifampicin resistance was 22.68% and 4.50%, respectively, out of 2451 samples tested on Xpert assay. Of total 990 presumptive tuberculosis tested [16], the estimated prevalence of M.tuberculosis in presumptive TB patients was 13.8% (95%CI: 11.88%-16.16%), and the estimated prevalence of rifampicin resistant in M.tuberculosis confirmed patients was 10.2% (4.97%-15.1%).…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Access the Diagnostic Accuracy of GeneXpert to Detect <em>Mycobacterium tuberculosis</em> and Rifampicin-Resistance Tuberculosis among Presumptive Tuberculosis and Presumptive Drug Resistant Tuberculosis Patients

Ramachandra,

Brammacharry,

Muralidhar

et al. 2023

Preprint

View full text Add to dashboard Cite

Xpert MTB/RIF is rapid molecular diagnostic tool capable of simultaneously detecting Mycobacterium tuberculosis and rifampicin resistance. This study aimed to access the diagnostic precision of Xpert MTB/RIF assay to detect pulmonary and extra-pulmonary tuberculosis and to evaluate the performance for the detection of rifampicin resistance. Of 37695 samples, 7156(18.98%) were tuberculosis positive, 509(7.11%) were rifampicin-resistant. The sensitivity, specificity, PPV, NPV, Diseases prevalence and accuracy of Xpert MTB/RIF assay for PTB were 99.87% (95%CI:99.75-99.94), 99.92%(95%CI:99.88-99.95), 99.71%(95%CI:99.54-99.82),99.97%(95%CI:99.93-99.98),21.38% (95%CI:20.92-21.86),and 99.91%(95%CI:99.87-99.94), respectively. For EPTB, the sensitivity, specificity, PPV, NPV, Diseases prevalence and accuracy of Xpert MTB/RIF assay accounted for 99.45% (95%CI:98.73-99.82),99.84%(95%CI:99.73-99.92),98.70%(95%CI:97.73-99.25),99.93% (95%CI:99.84-99.97),10.64%(95%CI:9.99-11.31),and 99.80%(95%CI:99.68-99.88), respectively. Despite its high sensitivity for detecting tuberculosis and rifampicin resistance, Xpert MTB/RIF had contradictory results for 20.5% of cases among patients with negative smear results and 54.9% of cases among patients with a high risk of Multidrug-resistant tuberculosis. Of 47 fluoroquinolone-resistant, 16.56% (26/157) of Multidrug-resistant tuberculosis isolates and 4.02% (20/498) isoniazid-resistant are fluoroquinolone-resistant, a characteristic distribution leading to about 17.2% of fluoroquinolone resistance events and relevant marker gyr-A mutations in MDR tuberculosis isolates. Further, our study indicated that increased fluoroquinolone resistance among Rifampicin-resistant and isoniazid-resistant tuberculosis endangers the success of newly endorsed MDR-TB regimens.

show abstract

Section: Discussioncontrasting

confidence: 59%

Section: Discussionmentioning

confidence: 98%

Access the Diagnostic Accuracy of GeneXpert to Detect <em>Mycobacterium tuberculosis</em> and Rifampicin-Resistance Tuberculosis among Presumptive Tuberculosis and Presumptive Drug Resistant Tuberculosis Patients

Ramachandra,

Brammacharry,

Muralidhar

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The incidence rate of M. tuberculosis (18.33%) in this study was higher than the previous study that reported 6.5% [18] and 7.9% [19] in Ethiopia, 13.8% [20] in Nepal, and 12% [21] in India. The incidence rate of M. tuberculosis infection among total suspects (n = 39,107) tested for GeneXpert MTB/RIF was 18.98% (7156/37,695), which is lower than the previous study that reported 38.77% [22] in China, 22.65% [23] and 22.9% [24] in Nigeria, and 23.82% [25] in India. The 3.26% positivity among the 8581 extrapulmonary samples tested for tuberculosis using the GeneXpert MTB/RIF assay in this study is lower than in the previous study (13%) conducted by Anwar et al [26].…”

Section: Discussioncontrasting

confidence: 58%

Assess the Diagnostic Accuracy of GeneXpert to Detect Mycobacterium tuberculosis and Rifampicin-Resistant Tuberculosis among Presumptive Tuberculosis and Presumptive Drug Resistant Tuberculosis Patients

Ramachandra,

Brammacharry,

Muralidhar

et al. 2023

Microbiology Research

View full text Add to dashboard Cite

GeneXpert MTB/RIF is a rapid molecular diagnostic tool capable of simultaneously detecting Mycobacterium tuberculosis and rifampicin resistance. This study aimed to assess the diagnostic precision of GeneXpert MTB/RIF assay to detect pulmonary and extrapulmonary tuberculosis and evaluate the performance for detecting of rifampicin resistance. Of 37,695 samples, 7156 (18.98%) were tuberculosis-positive, and 509 (7.11%) were rifampicin-resistant. The sensitivity, specificity, positive predictive value, negative predictive value, disease prevalence, and accuracy of the GeneXpert MTB/RIF assay for pulmonary tuberculosis were 99.87% (95%CI: 99.75–99.94), 99.92% (95%CI: 99.88–99.95), 99.71% (95%CI: 99.54–99.82), 99.97% (95%CI: 99.93–99.98), 21.38% (95%CI: 20.92–21.86), and 99.91% (95%CI: 99.87–99.94), respectively. For extrapulmonary tuberculosis, the sensitivity, specificity, PPV, NPV, disease prevalence, and accuracy of GeneXpert MTB/RIF assay accounted for 99.45% (95%CI: 98.73–99.82), 99.84% (95%CI: 99.73–99.92), 98.70% (95%CI: 97.73–99.25), 99.93% (95%CI: 99.84–99.97), 10.64% (95%CI: 9.99–11.31), and 99.80% (95%CI: 99.68–99.88), respectively. Despite its high sensitivity for detecting tuberculosis and rifampicin resistance, GeneXpert MTB/RIF had contradictory results for 20.5% of cases among patients with smear-negative results and 54.9% of cases among patients with a high risk of multidrug-resistant tuberculosis. Of 46% fluoroquinolone-resistant cases, 16.56% (26/157) were multidrug-resistant tuberculosis isolates, and 4.02% (20/498) were isoniazid-resistant, a characteristic distribution leading to about 17.2% of fluoroquinolone-resistance events and relevant marker gyr-A mutations in MDR tuberculosis isolates. Further, our study indicated that increased fluoroquinolone resistance among rifampicin-resistant and isoniazid-resistant tuberculosis endangers the success of newly endorsed MDR-TB regimens.

show abstract

“…Healthcare-associated pathogenic viruses and bacteria can affect human health significantly, such as coronavirus (COVID-19), 1,2 hepatitis virus, 3,4 influenza virus, 5,6 SARS coronavirus, 7,8 and Mycobacterium tuberculosis , 9,10 and have raised considerable global concerns. Pathogenic viruses or bacteria can cause severe health issues, and sometimes lethal risks if the pathogen is not identified in time.…”

Section: Introductionmentioning

confidence: 99%

Lateral flow assay of pathogenic viruses and bacteria in healthcare

Nan¹,

Yao²,

Li³

et al. 2023

Analyst

View full text Add to dashboard Cite

show abstract

Trends in the incidence of Rifampicin resistant Mycobacterium tuberculosis infection in northeastern Nigeria

Cited by 4 publications

References 33 publications

Access the Diagnostic Accuracy of GeneXpert to Detect <em>Mycobacterium tuberculosis</em> and Rifampicin-Resistance Tuberculosis among Presumptive Tuberculosis and Presumptive Drug Resistant Tuberculosis Patients

Access the Diagnostic Accuracy of GeneXpert to Detect <em>Mycobacterium tuberculosis</em> and Rifampicin-Resistance Tuberculosis among Presumptive Tuberculosis and Presumptive Drug Resistant Tuberculosis Patients

Assess the Diagnostic Accuracy of GeneXpert to Detect Mycobacterium tuberculosis and Rifampicin-Resistant Tuberculosis among Presumptive Tuberculosis and Presumptive Drug Resistant Tuberculosis Patients

Lateral flow assay of pathogenic viruses and bacteria in healthcare

Contact Info

Product

Resources

About